Treatment and surgery of abdominal septic states : comparison of two antibiotic therapies

A prospective, randomized controlled study was carried out in 104 patients to compare clavulanate-potentiated amoxycillin ('Augmentin') with a combination of cephalosporins (cefazoline and cefadroxil) supplemented with metronidazole in the treatment of abdominal septic states, suspected or...

Description complète

Détails bibliographiques
Publié dans:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 5(1989), 5 vom: 26., Seite 355-63
Auteur principal: Levi, D (Auteur)
Autres auteurs: Lemba, P, Amery, K
Format: Article
Langue:French
Publié: 1989
Accès à la collection:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Sujets:Clinical Trial Comparative Study English Abstract Journal Article Randomized Controlled Trial Clavulanic Acids Metronidazole 140QMO216E Cefadroxil 280111G160 plus... Amoxicillin-Potassium Clavulanate Combination 74469-00-4 Amoxicillin 804826J2HU Cefazolin IHS69L0Y4T
Description
Résumé:A prospective, randomized controlled study was carried out in 104 patients to compare clavulanate-potentiated amoxycillin ('Augmentin') with a combination of cephalosporins (cefazoline and cefadroxil) supplemented with metronidazole in the treatment of abdominal septic states, suspected or proven after surgical intervention. Patients on 'Augmentin' received 1.2 g (1 g amoxycillin plus 200 mg clavulanic acid) intravenously 3-times daily for a mean of 6.6 days, then 375 mg (250 amoxycillin plus 125 mg clavulanic acid) orally for a further 6.4 days. Patients on the standard therapy received 1 g cefazoline intravenously 4-times daily plus 500 mg metronidazole intravenously 3-times daily for 7 days, then 500 mg cefadroxil orally 4-times daily for a mean of 6.6 days. Evaluation of the patients' condition was undertaken after 24 hours, 3 days and 7 days. The results showed a significantly better response to treatment in the 'Augmentin' group, as judged by the amelioration of clinical symptoms, bacteriological findings, and tolerance. All the patients treated with 'Augmentin' showed an excellent or satisfactory overall response at Day 7 compared with 76% of those receiving the standard therapy
Description:Date Completed 25.08.1989
Date Revised 21.11.2013
published: Print
Citation Status MEDLINE